582 related articles for article (PubMed ID: 30361418)
21. Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy.
Khogeer H; Rahman H; Jain N; Angelova EA; Yang H; Quesada A; Ok CY; Sui D; Wei P; Al Fattani A; Pierce S; Loghavi S; Lamb A; Hu P; Thakral B; Kanagal-Shamanna R; Jorgensen JL; Jabbour EJ; Kantarjian HM; Medeiros LJ; Khoury JD
Br J Haematol; 2019 Aug; 186(4):538-548. PubMed ID: 31115909
[TBL] [Abstract][Full Text] [Related]
22. Distinct expression patterns of CD123 and CD34 on normal bone marrow B-cell precursors ("hematogones") and B lymphoblastic leukemia blasts.
Hassanein NM; Alcancia F; Perkinson KR; Buckley PJ; Lagoo AS
Am J Clin Pathol; 2009 Oct; 132(4):573-80. PubMed ID: 19762535
[TBL] [Abstract][Full Text] [Related]
23. Iron protects childhood acute lymphoblastic leukemia cells from methotrexate cytotoxicity.
Abedi M; Rahgozar S; Esmaeili A
Cancer Med; 2020 May; 9(10):3537-3550. PubMed ID: 32176452
[TBL] [Abstract][Full Text] [Related]
24. hTERT promoter methylation and telomere length in childhood acute lymphoblastic leukemia: associations with immunophenotype and cytogenetic subgroup.
Borssén M; Cullman I; Norén-Nyström U; Sundström C; Porwit A; Forestier E; Roos G
Exp Hematol; 2011 Dec; 39(12):1144-51. PubMed ID: 21914494
[TBL] [Abstract][Full Text] [Related]
25. CD16
Williams BA; Wang XH; Leyton JV; Maghera S; Deif B; Reilly RM; Minden MD; Keating A
Haematologica; 2018 Oct; 103(10):1720-1729. PubMed ID: 29976748
[TBL] [Abstract][Full Text] [Related]
26. The immunophenotypes of blast cells in B-cell precursor acute lymphoblastic leukemia: how different are they from their normal counterparts?
Sędek Ł; Bulsa J; Sonsala A; Twardoch M; Wieczorek M; Malinowska I; Derwich K; Niedźwiecki M; Sobol-Milejska G; Kowalczyk JR; Mazur B; Szczepański T
Cytometry B Clin Cytom; 2014 Sep; 86(5):329-39. PubMed ID: 24845957
[TBL] [Abstract][Full Text] [Related]
27. Precursor B- or T-lymphoblastic lymphoma presenting with cutaneous involvement: a series of 13 cases including 7 cases of cutaneous T-lymphoblastic lymphoma.
Lee WJ; Moon HR; Won CH; Chang SE; Choi JH; Moon KC; Lee MW
J Am Acad Dermatol; 2014 Feb; 70(2):318-25. PubMed ID: 24314877
[TBL] [Abstract][Full Text] [Related]
28. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia.
Bride KL; Vincent TL; Im SY; Aplenc R; Barrett DM; Carroll WL; Carson R; Dai Y; Devidas M; Dunsmore KP; Fuller T; Glisovic-Aplenc T; Horton TM; Hunger SP; Loh ML; Maude SL; Raetz EA; Winter SS; Grupp SA; Hermiston ML; Wood BL; Teachey DT
Blood; 2018 Mar; 131(9):995-999. PubMed ID: 29305553
[TBL] [Abstract][Full Text] [Related]
29. [CD34(+)CD19(+) cells with CD123 overexpression are a novel prognostic marker in Ph chromosome-positive acute lymphoblastic leukemia].
Kong Y; Huang XJ; Hao L; Qin YZ; Jiang Q; Jiang H; Liu YR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):6-10. PubMed ID: 24598641
[TBL] [Abstract][Full Text] [Related]
30. Treatment of Recurrent Refractory Pediatric Pre-B Acute Lymphoblastic Leukemia Using Inotuzumab Ozogamicin Monotherapy Resulting in CD22 Antigen Expression Loss as a Mechanism of Therapy Resistance.
Paul MR; Wong V; Aristizabal P; Kuo DJ
J Pediatr Hematol Oncol; 2019 Nov; 41(8):e546-e549. PubMed ID: 30807395
[TBL] [Abstract][Full Text] [Related]
31. Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukemia in children.
Matherly LH; Taub JW; Wong SC; Simpson PM; Ekizian R; Buck S; Williamson M; Amylon M; Pullen J; Camitta B; Ravindranath Y
Blood; 1997 Jul; 90(2):578-89. PubMed ID: 9226157
[TBL] [Abstract][Full Text] [Related]
32. Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.
Han L; Jorgensen JL; Brooks C; Shi C; Zhang Q; Nogueras González GM; Cavazos A; Pan R; Mu H; Wang SA; Zhou J; Ai-Atrash G; Ciurea SO; Rettig M; DiPersio JF; Cortes J; Huang X; Kantarjian HM; Andreeff M; Ravandi F; Konopleva M
Clin Cancer Res; 2017 Jul; 23(13):3385-3395. PubMed ID: 28096272
[No Abstract] [Full Text] [Related]
33. In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia.
Iacobucci I; Di Rorà AG; Falzacappa MV; Agostinelli C; Derenzini E; Ferrari A; Papayannidis C; Lonetti A; Righi S; Imbrogno E; Pomella S; Venturi C; Guadagnuolo V; Cattina F; Ottaviani E; Abbenante MC; Vitale A; Elia L; Russo D; Zinzani PL; Pileri S; Pelicci PG; Martinelli G
J Hematol Oncol; 2015 Nov; 8():125. PubMed ID: 26542114
[TBL] [Abstract][Full Text] [Related]
34. Easy discrimination of hematogones from lymphoblasts in B-cell progenitor acute lymphoblastic leukemia patients using CD81/CD58 expression ratio.
Nagant C; Casula D; Janssens A; Nguyen VTP; Cantinieaux B
Int J Lab Hematol; 2018 Dec; 40(6):734-739. PubMed ID: 30113764
[TBL] [Abstract][Full Text] [Related]
35. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases.
Raponi S; De Propris MS; Intoppa S; Milani ML; Vitale A; Elia L; Perbellini O; Pizzolo G; Foá R; Guarini A
Leuk Lymphoma; 2011 Jun; 52(6):1098-107. PubMed ID: 21348573
[TBL] [Abstract][Full Text] [Related]
36. Differential WNT gene expression in various subtypes of acute lymphoblastic leukemia.
Memarian A; Vosough P; Asgarian-Omran H; Tabrizi M; Shabani M; Shokri F
Iran J Immunol; 2012 Mar; 9(1):61-71. PubMed ID: 22426169
[TBL] [Abstract][Full Text] [Related]
37. High ENT1 and DCK gene expression levels are a potential biomarker to predict favorable response to nelarabine therapy in T-cell acute lymphoblastic leukemia.
Akahane K; Murakami Y; Kagami K; Abe M; Harama D; Shinohara T; Watanabe A; Goi K; Nishi R; Yamauchi T; Kimura S; Takita J; Look AT; Minegishi M; Sugita K; Inukai T
Hematol Oncol; 2019 Oct; 37(4):516-519. PubMed ID: 31335977
[No Abstract] [Full Text] [Related]
38. [Expression of CD123 in lymphocytic leukemia and its significance for monitoring minimal residual diseases.].
Wang YF; Chen BG; Luo WD; Zheng R; Li BL
Zhonghua Xue Ye Xue Za Zhi; 2010 Apr; 31(4):244-8. PubMed ID: 20510041
[TBL] [Abstract][Full Text] [Related]
39. Triphenotypic acute leukemia with TRAP-positive blasts: A pathological rarity.
Sharma P; Asthana B; Tyagi S
Leuk Res; 2009 Jul; 33(7):e83-4. PubMed ID: 19237193
[No Abstract] [Full Text] [Related]
40. MEF2D-BCL9 Fusion Gene Is Associated With High-Risk Acute B-Cell Precursor Lymphoblastic Leukemia in Adolescents.
Suzuki K; Okuno Y; Kawashima N; Muramatsu H; Okuno T; Wang X; Kataoka S; Sekiya Y; Hamada M; Murakami N; Kojima D; Narita K; Narita A; Sakaguchi H; Sakaguchi K; Yoshida N; Nishio N; Hama A; Takahashi Y; Kudo K; Kato K; Kojima S
J Clin Oncol; 2016 Oct; 34(28):3451-9. PubMed ID: 27507882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
